BUTTEVANT, CORK — In a quiet household in County Cork, a family is measuring time not in months or years, but in the gradual, irreversible loss of physical independence. For Craig Coady and his 16-year-old son, Paudie, the devastating reality of Friedreich’s ataxia (FA) is not a theoretical healthcare policy discussion—it is an agonizing daily presence.
Last September, the family endured every parent’s worst nightmare when 13-year-old Rory Coady played a football match, ate his favorite meal of fish and chips with his father, and went to sleep, only to never wake up. A massive heart attack—a direct cardiac complication of Friedreich’s ataxia—had taken his life in the night.
Today, Paudie faces the exact same aggressive neurological decline. To compound the family’s unimaginable grief, Paudie’s mother, Della, is concurrently in the advanced stages of Huntington’s disease, leaving Craig as the sole full-time carer for his wife and remaining son.
Yet, unlike previous generations who faced FA with no therapeutic recourse, a proven treatment now exists. Skyclarys (omaveloxolone) is the first and only therapy authorized by the European Medicines Agency to slow the progression of Friedreich’s ataxia by up to 50%. But while it is reimbursed and accessible across 11 European nations, a bureaucratic standoff over pricing threatens to deny Paudie and 200 other Irish patients their right to a future.
The Human Reality of a Clinical Impasse
Friedreich’s ataxia is a rare, inherited genetic disorder that progressively damages the spinal cord, peripheral nerves, and the heart muscle. It methodically strips away a child’s ability to walk, coordinate movement, swallow, and speak.
For Paudie, the decline is visibly accelerating. Last year, the teenager was able to go on a family holiday without a wheelchair; this year, a wheelchair is mandatory. As Craig Coady told national broadcasters, his deepest fear is that without medication, Paudie will soon lose his voice entirely and the simple ability to “ask his daddy for a cup of tea or a glass of water.”
The psychological toll on the family is just as severe. Bearing the weight of his own mortality and his brother’s memory, Paudie recently told his father: “It’s okay Dad. If I do die, I’ll be with Rory.”
“We are talking about my child’s life, and I’ve already lost a child,” Craig Coady stated following the latest health board ruling. “To see Paudie every day and to say it to him yesterday evening, it wasn’t good news… I didn’t see a face like that until the day Rory passed.”
A Systemic Bottleneck: The Cost of a Life
The impasse surrounding Skyclarys underscores a long-standing structural conflict within Ireland’s rare disease drug approval mechanism.
On August 12, 2026, the HSE Drugs Group delivered what campaigners described as a “devastating blow,” officially recommending that Skyclarys not be reimbursed. The decision stemmed from the National Centre for Pharmacoeconomics (NCPE), which cited the drug’s €280,000-per-patient annual cost as “poor value for money” and substantially above standard cost-effectiveness thresholds.
THE BUREAUCRATIC PIPELINE OF DELAY
[EMA Approval] ──► [NCPE Review] ──► [HSE Drugs Group Rejection] ──► [Final HSE Mgmt Decision]
(EU Level) (Irish Agency) (Cited: "Poor Value for Money") (Slated for August 25, 2026)
While state bodies like the NCPE are tasked with managing finite healthcare budgets—noting a potential €160 million budget impact—patient advocacy organizations argue that rigid, mass-market cost-effectiveness frameworks are inherently prejudiced against orphan drugs. Because rare disease therapies target incredibly small patient populations, they will invariably fail traditional “value” metrics.
By framing a teenager’s survival as an “opportunity cost,” the system fails to account for the catastrophic societal, emotional, and long-term care costs of letting young citizens irreversibly deteriorate.
The August 25 Deadline: A Plea for Political Courage
The final decision on whether the state will fund Skyclarys now rests with the HSE’s senior management team, which is scheduled to meet on August 25, 2026.
With the deadline looming, public representatives across Cork, rare disease advocates, and the Coady family are mounting a desperate plea for high-level political intervention. Craig Coady has directly appealed to the highest offices of government, urging Taoiseach Micheál Martin and the Minister for Health to bypass the bureaucratic deadlock and authorize emergency reimbursement.
| The Call to Action | Required Legislative & Executive Steps |
| Immediate Intervention | Executive directive to the HSE management team to overturn the Drugs Group recommendation ahead of the August 25 deadline. |
| Orphan Drug Fund | Establishment of a ring-fenced national fund specifically for rare disease treatments to bypass standard mass-market ICER evaluations. |
| Compassionate Access | Launching an immediate interim access scheme for rapidly deteriorating patients while commercial negotiations with the manufacturer (Biogen) conclude. |
“The HSE are there to save people’s lives,” Craig Coady urged. “There is a drug there. It is working… I am begging the Government, the HSE, and Biogen, please get together. I can’t lose him. He is all I have left.”
For the 200 patients in Ireland suffering from Friedreich’s ataxia, this is no longer just a debate over pharmaceutical pricing. It is a profound test of the state’s humanity, and a question of whether a nation will allow its young people to fade away while a lifeline waits just beyond a wall of red tape.
Government-Buildings-Dublin-Ireland-by-David-Kernan.
